OBJECTIVES: To describe the achievement of inactive disease (ID) and remission in polyarticular juvenile idiopathic arthritis (JIA) and to measure the associations among patient characteristics, imaging results and these outcomes. METHODS: We performed a retrospective cohort study of children with polyarticular JIA diagnosed and treated at Seattle Children's Hospital between 1 January 2000 and 31 December 2006. Each patient's disease status (active disease vs ID) was determined for every clinic visit. Adjusted relative risk estimates were obtained using Mantel-Haenszel methods. RESULTS: One hundred and four children were included. Patients were followed up for an average of 30 months. Patients achieved 138 episodes of ID. Fifty-one patients achieved 69 episodes of clinical remission on medication. When duration of active disease was summed over each patient's follow-up, patients spent a mean of 66.3% of their follow-up with active disease. Patients with evidence of joint damage on imaging studies obtained within 6 months of their first clinic visit spent a mean of 79% of their follow-up with active disease. Patients without these findings spent a mean of 58.5% of their follow-up with active disease (P < 0.001). Children who were RF(+) and children with early evidence of joint damage tended to have a higher prevalence of active disease during the follow-up period. CONCLUSIONS: In this cohort, children with polyarticular JIA spent the majority of their follow-up with active disease. Because children with early radiographic evidence of joint damage and children who were RF(+) tended to have the most active disease, improving outcomes for these subgroups may be an important goal for prospective study.
OBJECTIVES: To describe the achievement of inactive disease (ID) and remission in polyarticular juvenile idiopathic arthritis (JIA) and to measure the associations among patient characteristics, imaging results and these outcomes. METHODS: We performed a retrospective cohort study of children with polyarticular JIA diagnosed and treated at Seattle Children's Hospital between 1 January 2000 and 31 December 2006. Each patient's disease status (active disease vs ID) was determined for every clinic visit. Adjusted relative risk estimates were obtained using Mantel-Haenszel methods. RESULTS: One hundred and four children were included. Patients were followed up for an average of 30 months. Patients achieved 138 episodes of ID. Fifty-one patients achieved 69 episodes of clinical remission on medication. When duration of active disease was summed over each patient's follow-up, patients spent a mean of 66.3% of their follow-up with active disease. Patients with evidence of joint damage on imaging studies obtained within 6 months of their first clinic visit spent a mean of 79% of their follow-up with active disease. Patients without these findings spent a mean of 58.5% of their follow-up with active disease (P < 0.001). Children who were RF(+) and children with early evidence of joint damage tended to have a higher prevalence of active disease during the follow-up period. CONCLUSIONS: In this cohort, children with polyarticular JIA spent the majority of their follow-up with active disease. Because children with early radiographic evidence of joint damage and children who were RF(+) tended to have the most active disease, improving outcomes for these subgroups may be an important goal for prospective study.
Authors: Sarah Ringold; Pamela F Weiss; Robert A Colbert; Esi Morgan DeWitt; Tzielan Lee; Karen Onel; Sampath Prahalad; Rayfel Schneider; Susan Shenoi; Richard K Vehe; Yukiko Kimura Journal: Arthritis Care Res (Hoboken) Date: 2014-07 Impact factor: 4.794
Authors: Elham Rezaei; Daniel Hogan; Brett Trost; Anthony J Kusalik; Gilles Boire; David A Cabral; Sarah Campillo; Gaëlle Chédeville; Anne-Laure Chetaille; Paul Dancey; Ciaran Duffy; Karen Watanabe Duffy; John Gordon; Jaime Guzman; Kristin Houghton; Adam M Huber; Roman Jurencak; Bianca Lang; Kimberly Morishita; Kiem G Oen; Ross E Petty; Suzanne E Ramsey; Rosie Scuccimarri; Lynn Spiegel; Elizabeth Stringer; Regina M Taylor-Gjevre; Shirley M L Tse; Lori B Tucker; Stuart E Turvey; Susan Tupper; Rae S M Yeung; Susanne Benseler; Janet Ellsworth; Chantal Guillet; Chandima Karananayake; Nazeem Muhajarine; Johannes Roth; Rayfel Schneider; Alan M Rosenberg Journal: Rheumatology (Oxford) Date: 2020-09-01 Impact factor: 7.580